| Systematic (IUPAC) name | |
|---|---|
| (6R,7S)-7-[[(2S)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | |
| Clinical data | |
| Trade names | Lorabid |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a601206 |
| Pregnancy cat. | ? |
| Legal status | ? |
| Pharmacokinetic data | |
| Protein binding | 25% |
| Identifiers | |
| CAS number | 76470-66-1 |
| ATC code | J01DC08 |
| PubChem | CID 5284584 |
| DrugBank | DB00447 |
| ChemSpider | 4447634 |
| UNII | W72I5ZT78Z |
| KEGG | D08143 |
| ChEMBL | CHEMBL1013 |
| Chemical data | |
| Formula | C16H16ClN3O4 |
| Mol. mass | 349.769 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Loracarbef is an antibiotic.[1] Its use was discontinued in 2006.[citation needed] It is a carbacephem, but it is sometimes grouped together with the second-generation cephalosporin antibiotics. It was marketed under the trade name Lorabid. Loracarbef is a synthetic "carba" analogue of cefaclor, and is more stable chemically. Diarrhea is the most common adverse effect with Loracarbef. Side effects are more frequently seen with children under the age of twelve. It received FDA approval in 1991.
| This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)